Dark

ALXN
Alexion Pharmaceuticals Inc
stock NASDAQ

Inactive

Jul 20, 2021

182.50USD+1.700%(+3.05)90,506,123

Pre-market

0.00USD-100.000%(-179.45)0

After-hours

0.00USD0.000%(0.00)0

OverviewHistoricalExchangesShortsNews

Oct 27, 2021

04:03PM EDT Alexion Pharmaceuticals Inc. (ALXN) Declares Quarterly Dividend of $ 4.50, Record Date 11/8/2021 RTTNews

Aug 26, 2021

02:35AM EDT British drug major AstraZeneca (AZN.L, AZN) said that FoCus Phase III trial in Wilson disease showed ALXN1840 met the primary endpoint with a statistically significant improvement in daily mean copper mobilisation from tissues. ALXN1840 demonstrated approximately three times greater copper mobilisation from tissues than standard-of-care treatments. RTTNews

Jul 21, 2021

08:47AM EDT AstraZeneca Completes Alexion Acquisition Benzinga

Jul 20, 2021

02:37PM EDT Alexion's Ultomiris Sales Almost Doubles In 1H 2021 As $39B AstraZeneca Deal Looms Benzinga

Jul 16, 2021

07:29AM EDT Alexion's Ultomiris Shows Compelling, Durable Efficacy In Rare Muscle Weakness Disorder Benzinga

Jul 15, 2021

08:53PM EDT Moderna Inc. (MRNA) will replace Alexion Pharmaceuticals Inc. (ALXN) in the S&P 500 effective prior to the opening of trading on Wednesday, July 21, S&P Dow Jones Indices said in a statement. RTTNews

07:02PM EDT Moderna Set to Join S&P 500 PR Newswire

05:17PM EDT S&P Dow Jones Indices Announces Moderna To Join S&P 500, Will Replace Alexion Benzinga

04:12PM EDT Alexion Announces Phase 3 Study Of ULTOMIRIS In Generalized Myasthenia Gravis Met Its Primary Endpoint Benzinga

04:05PM EDT Alexion Announces Positive Topline Results from Phase 3 Study of ULTOMIRIS(r) (ravulizumab-cwvz) in Adults with Generalized Myasthenia Gravis (gMG) Business Wire

08:08AM EDT The Daily Biotech Pulse: Galapagos Sinks On Data, J&J Recalls Sunscreen Products, FibroGen Awaits AdCom Verdict, 3 IPOs Benzinga

Jul 14, 2021

08:01PM EDT Honeywell International Inc. to Join the NASDAQ-100 Index GlobeNewswire Inc

02:27AM EDT The UK Competition and Markets Authority or CMA has approved AstraZeneca Plc.'s (AZN.L, AZN) proposed acquisition of Alexion Pharmaceuticals Inc. (ALXN). The acquisition is expected to close on 21 July 2021. RTTNews

Jul 13, 2021

08:05AM EDT The Daily Biotech Pulse: Equillium Issues Positive Regulatory Update, Biogen In-Licenses Multiple Sclerosis Drug, Aridis Releases COVID-19 Antibody Cocktail Data Benzinga

Jul 6, 2021

05:21AM EDT AstraZeneca Announced Receipt of Clearance from the European Commission for the Proposed Acquisition of Alexion Benzinga

Jul 2, 2021

07:38AM EDT The Daily Biotech Pulse: Iterum's Regulatory Setback, Decision Day For Provention Bio, Cidara & Outset Medical Announce CFO Departures Benzinga

Jun 29, 2021

08:17AM EDT The Daily Biotech Pulse: Sanofi Bets Big On mRNA Tech, Decision Day For MediWound, DiaMedica Issues Kidney Disease Data Readout Benzinga

Jun 17, 2021

08:33AM EDT The Daily Biotech Pulse: Biogen Faces Another Clinical Setback, CureVac's COVID-19 Vaccine Study Fails, Moment Of Reckoning For Orphazyme Benzinga

Jun 11, 2021

08:05AM EDT The Daily Biotech Pulse: Vertex Shelves Mid-Stage Study, Precigen & Novan Jump On Data, Hematology Conference, Janux Debuts Benzinga

03:05AM EDT Caelum Biosciences And Alexion Announce New Phase 2 Safety And Tolerability Data For CAEL-101 RTTNews

03:01AM EDT Caelum and Alexion Present Additional Phase 2 Data Reinforcing Safety and Tolerability of CAEL-101 in AL Amyloidosis at the European Hematology Association Congress 2021 Business Wire

Jun 10, 2021

08:13AM EDT The Daily Biotech Pulse: US To Procure 500M Pfizer-BioNTech Vaccine Doses For Donation, Verona Out-Licenses COPD Drug, Nautilus Lists Through SPAC Deal Benzinga

Jun 7, 2021

01:55PM EDT Alexion Reports FDA Approval Of ULTOMIRIS For Children, Adolescents With Paroxysmal Nocturnal Hemoglobinuria Benzinga

01:55PM EDT Alexion Announces FDA Approval of ULTOMIRIS(r) (ravulizumab-cwvz) for Children and Adolescents with Paroxysmal Nocturnal Hemoglobinuria (PNH) Business Wire

Jun 3, 2021

08:02AM EDT Diversifying to Conquer: Fortress Biotech (FBIO) Partnering Expansion Driving Progress in Cancer Immunotherapy and Rare Disease Therapeutics Benzinga

Jun 2, 2021

10:38AM EDT Attention Biotech Investors: Mark Your Calendar For June PDUFA Dates Benzinga

May 25, 2021

07:54AM EDT UK Competition Watchdog Probes AstraZeneca's $39B Alexion Takeover Benzinga

05:11AM EDT AstraZeneca Said CMA Review of Alexion Deal is Another Step Towards Closing the Deal, Expected in Q3 Benzinga

May 21, 2021

07:26AM EDT The Daily Biotech Pulse: Moderna's Vaccine Authorized In Japan, Neovasc's Adverse Ruling In Germany, Metacrine Rallies On Insider Buying Benzinga

May 19, 2021

07:30AM EDT The Daily Biotech Pulse: Iovance To Delay Regulatory Filing For Cancer Therapy, Departures At Passage Bio, Positive Readout For Silence Therapeutics Benzinga

May 18, 2021

07:44AM EDT The Daily Biotech Pulse: Spero Secures NIAID Funding, GlaxoSmithKline Releases COVID-19 Data, BioNTech Gets New CFO Benzinga

May 14, 2021

07:59AM EDT The Daily Biotech Pulse: CorMedix Slumps On Delay In Resubmission of DefenCath NDA, Apellis Awaits FDA Decision, Vera Therapeutics Debuts Benzinga

May 13, 2021

08:10AM EDT The Daily Biotech Pulse: Merck Reports Positive Keytruda Data In Breast Cancer, Curis, Evoke Slump On Earnings, Qiagen's Rapid COVID-19 Antibody Test OK'ed For Emergency Use Benzinga

May 12, 2021

04:14PM EDT Caelum and Alexion Announce Upcoming CAEL-101 Data Presentations at the European Hematology Association Congress 2021 Business Wire

04:01PM EDT Alexion Announces Upcoming Data Presentations at the 26th European Hematology Association Virtual Congress Business Wire

May 11, 2021

09:47AM EDT Alexion Pharmaceuticals Inc. (ALXN) said that its shareholders have approved proposed acquisition by AstraZeneca Plc. (AZN.L, AZN). The acquisition is expected to close in the third quarter of 2021. RTTNews

09:32AM EDT Alexion Shareholders Approve Acquisition By AstraZeneca; Deal Expected To Close In Q3 RTTNews

09:30AM EDT Alexion Pharma Reports Shareholders Voted To Adopt, Approve Previously-Announced Acquisition By AstraZeneca Benzinga

09:28AM EDT Alexion Shareholders Approve Acquisition by AstraZeneca Business Wire

07:54AM EDT The Daily Biotech Pulse: FDA Authorizes Pfizer-BioNTech COVID-19 Vaccine For Adolescents, Lilly Strikes R&D Collaboration, Vaccine Stocks Novavax, Inovio Sink On Earnings Benzinga

Apr 30, 2021

08:16AM EDT Recap: Alexion Pharmaceuticals Q1 Earnings Benzinga

08:13AM EDT Alexion Pharmaceuticals Inc. (ALXN) revealed earnings for its first quarter that rose from the same period last year. RTTNews

08:05AM EDT Alexion Pharma Q1 GAAP EPS $2.86; Non-GAAP EPS $3.52 RTTNews

08:02AM EDT Alexion Pharmaceuticals Q1 Adj. EPS $3.52 Beats $3.16 Estimate, Sales $1.64B Beat $1.58B Estimate Benzinga

08:00AM EDT Alexion Reports First Quarter 2021 Results Business Wire

07:31AM EDT The Daily Biotech Pulse: Hyperphosphatemia Drug Regulatory Review Extended, Phathom Pharma Data Readout, 2 IPOs Benzinga

04:12AM EDT Earnings Scheduled For April 30, 2021 Benzinga

Apr 29, 2021

10:15AM EDT Earnings Outlook For Alexion Pharmaceuticals Benzinga

Apr 28, 2021

05:00PM EDT UPDATED Alexion to Report First Quarter 2021 Results on Friday, April 30, 2021 Business Wire

Apr 22, 2021

08:09AM EDT The Daily Biotech Pulse: KemPharm Receives $10M Milestone Payment, Zymergen, Neuropace Debut On Nasdaq, Renalytix Wins US Government Contract, 2 IPOs Benzinga

Apr 21, 2021

07:31AM EDT The Daily Biotech Pulse: Moderna To Supply Variant-Specific Vaccine To Israel, Roche's Diagnostics Business Comes to Rescue Benzinga

Apr 20, 2021

08:07AM EDT The Daily Biotech Pulse: Q1 Beat From Johnson & Johnson, KalVista Study Placed On Hold, European Label Expansion For GW Pharma's Epidiolex Benzinga

08:00AM EDT Alexion to Report First Quarter 2021 Results on Monday, May 3, 2021 Business Wire

Apr 16, 2021

08:50AM EDT British drug major AstraZeneca Plc. (AZN.L, AZN) said Friday that it has received a clearance from the U.S. Federal Trade Commission for its proposed acquisition of Alexion Pharmaceuticals Inc (ALXN). It follows the conclusion of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act. RTTNews

07:04AM EDT AstraZeneca Announces US Clearance Of Proposed Acquisition Of Alexion; Says Acquisition Remains Expected To Close In Q3 2021 Benzinga

Mar 23, 2021

10:04AM EDT Benzinga's Top Ratings Upgrades, Downgrades For March 23, 2021 Benzinga

08:14AM EDT 10 Biggest Price Target Changes For Tuesday Benzinga

07:03AM EDT SVB Leerink Downgrades Alexion Pharmaceuticals to Market Perform, Lowers Price Target to $156 Benzinga

Mar 4, 2021

04:56PM EST Alexion Announces Upcoming Data Presentations at the 73rd Annual Meeting of the American Academy of Neurology Business Wire

Mar 1, 2021

09:20AM EST AstraZeneca Divests Entire 7.7% Stake In Moderna For $1B: The Times Benzinga

08:02AM EST INVESTIGATION ALERT: Halper Sadeh LLP Investigates the Following Companies on PR Newswire

Feb 28, 2021

10:19PM EST AstraZeneca Divests Entire 7.7% Stake In Moderna For $1B: The Times Benzinga

Feb 20, 2021

02:11PM EST INVESTIGATION ALERT: Halper Sadeh LLP Investigates the Following Companies on PR Newswire

Feb 19, 2021

06:50PM EST SHAREHOLDER ALERT: WeissLaw LLP Reminds GIX, ALXN, STPK, and BRPA Shareholders PR Newswire

Feb 13, 2021

12:06PM EST INVESTIGATION ALERT: Halper Sadeh LLP Investigates MDCA, FFG, ALXN, NK, HLIX; PR Newswire

Feb 12, 2021

12:12PM EST SHAREHOLDER ALERT: WeissLaw LLP Reminds NPA, THBR, GIX, and ALXN Shareholders PR Newswire

Feb 6, 2021

11:52AM EST INVESTIGATION ALERT: Halper Sadeh LLP Investigates NK, ALXN, CATM, CGIX, MTSC; PR Newswire

Feb 5, 2021

02:06PM EST SHAREHOLDER ALERT: WeissLaw LLP Reminds NPA, THBR, GIX, and ALXN Shareholders PR Newswire

08:43AM EST SVB Leerink Maintains Outperform on Alexion Pharmaceuticals, Lowers Price Target to $196 Benzinga

Feb 4, 2021

08:35AM EST Earnings Scheduled For February 4, 2021 Benzinga

08:15AM EST Alexion Pharmaceuticals Inc. (ALXN) revealed earnings for fourth quarter that dropped from the same period last year. RTTNews

08:09AM EST Alexion Q4 Total Revenues $1.59 Bln, 15% Increase From Last Year RTTNews

08:04AM EST Alexion Reports Fourth Quarter and Full Year 2020 Results Business Wire

08:01AM EST Alexion Pharmaceuticals Q4 Adj. EPS $2.96 Beats $2.56 Estimate, Sales $1.59B Beat $1.52B Estimate Benzinga

07:22AM EST The Daily Biotech Pulse: Novartis COVID-19 Drug Readout, Merck And Roche Earnings, 3 IPOs Benzinga

Jan 30, 2021

05:03PM EST Halper Sadeh LLP Continues to Investigate the Following Mergers; Shareholders PR Newswire

01:19PM EST The Week Ahead In Biotech: Merck, Pfizer In Earnings Mix, Plus Adamas, Mallinckrodt FDA Decisions, IPOs And More Benzinga

Jan 29, 2021

04:26PM EST SHAREHOLDER ALERT: WeissLaw LLP Reminds THBR, GIX, ALXN and STPK Shareholders PR Newswire

Jan 27, 2021

02:25PM EST Chief Diversity Officers Take On New Visibility, Challenges Benzinga

07:36AM EST The Daily Biotech Pulse: Sorrento, Immutep Surge On COVID-19 Study Data, T2 Biosystems Sinks On Preannouncement Benzinga

Jan 26, 2021

08:07AM EST The Daily Biotech Pulse: Novartis Misses, J&J Beats In Big Pharma Earnings, Vaccine Developer CureVac Taps Equity Market Benzinga

Jan 25, 2021

04:05PM EST Alexion to Report Fourth Quarter and Full Year 2020 Results on Thursday, February 4, 2021 Business Wire

Jan 22, 2021

04:48PM EST ALEXION INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Alexion Pharmaceuticals, Inc. - ALXN Business Wire

03:43PM EST SHAREHOLDER ALERT: WeissLaw LLP Reminds NPA, THBR, GIX, and ALXN Shareholders PR Newswire

11:44AM EST ALERT: Halper Sadeh LLP Investigates the Following Companies on Behalf of PR Newswire

Jan 14, 2021

04:43PM EST INVESTIGATION ALERT: Halper Sadeh LLP Investigates ALXN, CHNG, RP, RNET, MDCA, PR Newswire

07:57AM EST The Daily Biotech Pulse: Alexion Pauses COVID-19 Study, NantKwest Readout, Organogenesis Jumps On Guidance, Trial Updates Benzinga

Jan 13, 2021

06:38PM EST SHAREHOLDER ALERT: WeissLaw LLP Reminds MTSC, IPHI, ALXN and XLNX Shareholders PR Newswire

04:24PM EST Alexion Says Its Will Conduct Further Analysis Of Its Phase 3 Study Of ULTOMIRIS To Determine The Next Step Benzinga

04:22PM EST Alexion Announces It Recommends Pausing Additional Enrollment For Phase 3 Study Of ULTOMIRIS For Hospitalized Patients with Severe COVID-19 Benzinga

04:22PM EST Alexion Announces It Recommends Pausing Additional Enrollment Benzinga

04:21PM EST Alexion Provides Update on Phase 3 Study of ULTOMIRIS(r) (ravulizumab-cwvz) in Hospitalized Patients with Severe COVID-19 Business Wire

Jan 12, 2021

07:07AM EST Alexion Pharmaceuticals Expects To Exceed High End Of 2020 Revenue Guidance Range Of Of $5.9B-$5.95B Benzinga

07:00AM EST Alexion Highlights Commercial, Clinical and Financial Progress at the 39th Annual J.P. Morgan Healthcare Conference Business Wire

Jan 8, 2021

10:54AM EST Raymond James Downgrades Alexion Pharmaceuticals to Market Perform Benzinga

Jan 7, 2021

01:55PM EST Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies: GlobeNewswire Inc

Jan 6, 2021

04:54PM EST SHAREHOLDER ALERT: WeissLaw LLP Reminds EIDX, IPHI, ALXN, and XLNX Shareholders PR Newswire

Jan 5, 2021

04:30PM EST Alexion to Present at the 39th Annual J.P. Morgan Healthcare Conference Business Wire

11:26AM EST ALERT: Halper Sadeh LLP Investigates ALXN, SPWH, CBMG, STND, EIDX; Shareholders PR Newswire

Jan 1, 2021

12:53PM EST Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies: GlobeNewswire Inc

Dec 30, 2020

08:49PM EST WeissLaw LLP Reminds MTSC, EIDX, IPHI, and ALXN Shareholders About Its Ongoing PR Newswire

Dec 24, 2020

10:59AM EST ALERT: Halper Sadeh LLP Continues to Investigate the Following Mergers - ALXN, PR Newswire

Dec 23, 2020

07:36AM EST Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies: GlobeNewswire Inc

Dec 21, 2020

07:56PM EST SHAREHOLDER ALERT: WeissLaw LLP Reminds TCF and ALXN Shareholders About Its PR Newswire

Dec 18, 2020

09:00PM EST SHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of PR Newswire

07:48AM EST The Daily Biotech Pulse: FDA Nod For Amgen's Biosimilar, Moderna's Vaccine Vote, Mesoblast Sinks On Data Benzinga

07:45AM EST The Daily Biotech Pulse: FDA Nod For Amgen's Biosimilar, Moderna's Vaccine Approved, Mesoblast Sinks On Data Benzinga

Dec 16, 2020

07:45PM EST & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Alexion Pharmaceuticals, Inc. - ALXN PR Newswire

01:01PM EST SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates the Following PR Newswire

11:25AM EST Benzinga's Top Upgrades, Downgrades For December 16, 2020 Benzinga

07:56AM EST Truist Securities Downgrades Alexion Pharmaceuticals to Hold, Raises Price Target to $175 Benzinga

Dec 15, 2020

07:45PM EST Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, has launched an investigation into whether the board members of Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) breached their fiduciary duties or violated the federal securities laws in connection with the companys acquisition by AstraZeneca PLC (NASDAQ: AZN). GlobeNewswire Inc

10:31AM EST Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies: GlobeNewswire Inc

09:42AM EST Benzinga's Top Upgrades, Downgrades For December 15, 2020 Benzinga

07:52AM EST The Daily Biotech Pulse: Mesoblast Releases Mixed Data, MediWound Jumps On Distribution Deal, Kezar Life Sciences Rallies On Index Inclusion, Opiant Gets BARA Funding Benzinga

06:35AM EST Citigroup Downgrades Alexion Pharmaceuticals to Neutral, Announces $175 Price Target Benzinga

Dec 14, 2020

06:20PM EST SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation GlobeNewswire Inc

04:05PM EST SHAREHOLDER ALERT: WeissLaw LLP Investigates Alexion Pharmaceuticals, Inc. PR Newswire

09:58AM EST Shares of Alexion Pharmaceuticals, Inc. (ALXN) are currently surging over 30% after AstraZeneca agreed to acquire the company. RTTNews

09:53AM EST P/E Ratio Insights for Alexion Pharmaceuticals Benzinga

09:51AM EST Benzinga's Top Upgrades, Downgrades For December 14, 2020 Benzinga

09:45AM EST Looking Into Alexion Pharmaceuticals's Return On Capital Employed Benzinga

08:16AM EST Credit Suisse Downgrades Alexion Pharmaceuticals to Neutral, Raises Price Target to $194 Benzinga

07:58AM EST BMO Capital Downgrades Alexion Pharmaceuticals to Market Perform, Raises Price Target to $175 Benzinga

07:57AM EST 10 Biggest Price Target Changes For Monday Benzinga

07:07AM EST What Does Alexion Pharmaceuticals Debt Look Like? Benzinga

06:41AM EST Baird Downgrades Alexion Pharmaceuticals to Neutral, Raises Price Target to $175 Benzinga

06:36AM EST Private Equity EQT Offers To Acquire Swedish Pharma Recipharm For $2.1B Benzinga

06:35AM EST SVB Leerink Maintains Outperform on Alexion Pharmaceuticals, Raises Price Target to $200 Benzinga

06:05AM EST A Peek Into The Markets: US Stock Futures Climb; Crude Oil Up 1% Benzinga

Dec 13, 2020

08:58PM EST (ALXN): Johnson Fistel Investigates Proposed Sale of Alexion Pharmaceuticals; PR Newswire

Dec 12, 2020

12:23PM EST AstraZeneca to Acquire Alexion for $60/Share in Cash Plus olders will receive $60 in cash and 2.1243 AstraZeneca ADSs Benzinga

11:21AM EST British drug major AstraZeneca Plc. (AZN.L, AZN) agreed to buy Alexion Pharmaceuticals Inc. (ALXN) for $175 per share in cash and stock, valuing the Boston-based company at $39 billion. RTTNews

10:24AM EST AstraZeneca To Buy Rare-Disease Specialist Drugmaker Alexion For $39 Billion Benzinga

09:36AM EST AstraZeneca to Acquire Alexion for $60/Share in Cash Benzinga

09:07AM EST Alexion Merger Investigation: Halper Sadeh LLP Announces Investigation Into Whether the Sale of Alexion Pharmaceuticals, Inc. Is Fair to Shareholders; Investors Are Encouraged to Contact the Firm - ALXN Business Wire

07:48AM EST AstraZeneca to Acquire Alexion, Accelerating the Company's Strategic and Financial Development Business Wire

Dec 6, 2020

08:41AM EST Week Ahead In Biotech: FDA To Decide On Emergency Use Of Pfizer's COVID Vaccine, Hematology Conference Presentations Pick Up Pace Benzinga

Nov 25, 2020

10:24AM EST Alexion Granted Orphan Drug Designation For Ravulizumab For 'Treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy' Benzinga

Nov 20, 2020

11:48AM EST Benzinga's Top Upgrades, Downgrades For November 20, 2020 Benzinga

05:53AM EST Bernstein Initiates Coverage On Alexion Pharmaceuticals with Market Perform Rating, Announces Price Target of $148 Benzinga

03:10AM EST Alexion Pharmaceuticals Inc. (ALXN) said Friday that the European Commission has approved the new 100 mg/mL intravenous formulation of Ultomiris or ravulizumab for the treatment of paroxysmal nocturnal hemoglobinuria or PNH and atypical hemolytic uremic syndrome or aHUS. RTTNews

02:25AM EST Alexion: EC Approves New 100 Mg/mL Intravenous Formulation Of ULTOMIRIS Or Ravulizumab RTTNews

02:00AM EST Alexion Receives Marketing Authorization from European Commission for New Formulation of ULTOMIRIS(r) (ravulizumab) with Significantly Reduced Infusion Time Business Wire

Nov 10, 2020

07:00AM EST Alexion to Present at Upcoming Virtual Investor Conferences Business Wire

Nov 4, 2020

11:55AM EST Caelum and Alexion Announce Upcoming Data Presentations at the 62nd American Society of Hematology Annual Meeting and Exposition Business Wire

11:50AM EST Alexion Pharma Highlights Upcoming Data Presentations At American Society Of Hematology Dec. 6, 7 Benzinga

11:50AM EST Alexion Announces Upcoming Data Presentations at the 62nd American Society of Hematology Annual Meeting and Exposition Business Wire

Oct 30, 2020

08:31AM EDT Morgan Stanley Maintains Equal-Weight on Alexion Pharmaceuticals, Lowers Price Target to $119 Benzinga

07:06AM EDT SVB Leerink Maintains Outperform on Alexion Pharmaceuticals, Lowers Price Target to $159 Benzinga

Oct 29, 2020

07:49AM EDT Alexion Pharmaceuticals: Q3 Earnings Insights Benzinga

07:30AM EDT The Daily Biotech Pulse: Novartis Acquires Gene Therapy Company, Moderna's Japanese Vaccine Supply Deal Benzinga

07:03AM EDT Alexion Pharma Raises FY20 Financial Guidance - Quick Facts RTTNews

06:41AM EDT UPDATE: Alexion Raises FY20 Guidance: Adj. EPS From $10.65-$10.95 To $11.70-$12 vs $11.30 Estimate, Sales From $5.55B-$5.6B To $5.9B-$5.95B vs $5.75B Est. Benzinga

06:41AM EDT Alexion Pharmaceuticals Inc. (ALXN) released a profit for its third quarter that advanced from last year. RTTNews

06:40AM EDT Alexion Raises Guidance Benzinga

06:40AM EDT Alexion Pharmaceuticals Q3 Adj. EPS $3.24 Beats $2.58 Estimate, Sales $1.59B Beat $1.42B Estimate Benzinga

06:34AM EDT Alexion Q3 GAAP EPS $2.62 Vs $2.08 Last Year RTTNews

06:30AM EDT Alexion Reports Third Quarter 2020 Results Business Wire

04:08AM EDT Earnings Scheduled For October 29, 2020 Benzinga

Oct 28, 2020

06:06PM EDT Notable Earnings Watchlist For Thursday, Oct. 29, 2020 Before Market Open: PCG, NOK, OSTK, KHC, SNY, RCL, K, RL, COHU, CMCSA, ABEV, ALXN, CS, TXT, XYL, YUM, TPR, TAP, SPOT, COP, ALKS, AAN, BAX, TPX, KDP, NEM, BC, APRN, BWA, DNKN, DD, HUN, TAK, BUD Benzinga

12:38PM EDT Benzinga's Top Upgrades, Downgrades For October 28, 2020 Benzinga

08:27AM EDT UBS Initiates Coverage On Alexion Pharmaceuticals with Neutral Rating, Announces Price Target of $133 Benzinga

Oct 20, 2020

04:30PM EDT Alexion to Report Third Quarter 2020 Results on Thursday, October 29, 2020 Business Wire

Oct 15, 2020

02:24PM EDT Alexion Pharmaceuticals Option Alert: Oct 23 $126 Calls at the Ask: 250 @ $2.15 vs 9 OI; Earnings 10/26 Before Open [est] Ref=$121.54 Benzinga

Oct 13, 2020

08:15AM EDT Morgan Stanley Maintains Equal-Weight on Alexion Pharmaceuticals, Raises Price Target to $121 Benzinga

Oct 12, 2020

08:34AM EDT Alexion Gets FDA Approval For New Advanced Formulation Of ULTOMIRIS With Significantly Reduced Infusion Time RTTNews

08:31AM EDT Alexion Receives FDA Approval For New Advanced Formulation Of ULTOMIRIS With Significantly Reduced Infusion Time Benzinga

08:30AM EDT Alexion Receives FDA Approval for New Advanced Formulation of ULTOMIRIS(r) (ravulizumab-cwvz) with Significantly Reduced Infusion Time Business Wire

Oct 9, 2020

02:02PM EDT Alexion Pharma Highlights Upcoming Data Presentations At American Society Of Nephrology's Virtual Kidney Week Oct. 22-25 Benzinga

02:00PM EDT Alexion Announces Upcoming Data Presentations at the American Society of Nephrology's Virtual Kidney Week 2020 Business Wire

11:24AM EDT Price Over Earnings Overview: Alexion Pharmaceuticals Benzinga

11:15AM EDT Alexion Speculated To Have Drawn Interest, Betaville Says Benzinga

Oct 6, 2020

07:06AM EDT Alexion Pharmaceuticals, Inc. (ALXN) announced Tuesday the continued progression of the company's LEAD-EXPAND-DIVERSIFY value-creation strategy and will highlight strategic advancements at the Virtual Investor Day later today. RTTNews

06:40AM EDT Alexion Pharma Sees 2025 Global Revenue Target Of $9 To $10 Bln; To Will Highlight Strategic Advancements RTTNews

06:31AM EDT Alexion Provides Pipeline Highlights For Virtual Investor Day Benzinga

06:30AM EDT Alexion Highlights Promising Pipeline & Distinguished Rare Disease Capabilities at Virtual Investor Day Business Wire

Sep 25, 2020

08:45AM EDT Alexion Pharmaceuticals Inc. (ALXN) said Friday that Japan has approved Ultomiris or ravulizumab for adults and children living with atypical hemolytic uremic syndrome or aHUS. RTTNews

08:35AM EDT Alexion Pharma: ULTOMIRIS Gets Approval In Japan For Atypical Hemolytic Uremic Syndrome In Adults And Children RTTNews

08:31AM EDT Alexion Pharmaceuticals Announces That ULTOMIRIS Receives Approval In Japan For Atypical Hemolytic Uremic Syndrome In Adults And Children Benzinga

08:30AM EDT ULTOMIRIS(r) (ravulizumab) Receives Approval in Japan for Atypical Hemolytic Uremic Syndrome (aHUS) in Adults and Children Business Wire

Sep 21, 2020

05:31AM EDT Alexion Announced CHMP Positive Opinion for New Advanced Formulation of ULTOMIRIS with Significantly Reduced Infusion Time Benzinga

02:16AM EDT Alexion Pharma: CHMP Adopts Positive Opinion For New RTTNews

02:03AM EDT Alexion Says CHMP Adopted Positive Opinion For New 100 Mg/mL IV Advanced Formulation Of ULTOMIRIS RTTNews

02:00AM EDT Alexion Receives CHMP Positive Opinion for New Advanced Formulation of ULTOMIRIS(r) (ravulizumab) with Significantly Reduced Infusion Time Business Wire

Sep 15, 2020

03:22PM EDT Hearing Biogen In Talks To Acquire Alexion; Biogen Is Working With Goldman Sachs On Its Interest In Alexion Benzinga

Sep 14, 2020

11:32AM EDT A Look Into Alexion Pharmaceuticals's Price Over Earnings Benzinga

08:07AM EDT Alexion and Caelum Biosciences Announce Start Of Phase 3 Studies Of CAEL-101 In AL Amyloidosis Benzinga

08:04AM EDT Alexion And Caelum Biosciences Announce Initiation Of CARES Phase 3 Clinical Program To Evaluate CAEL-101 RTTNews

08:00AM EDT Alexion and Caelum Biosciences Announce Start of Phase 3 Studies of CAEL-101 in AL Amyloidosis Business Wire

07:00AM EDT Alexion to Discuss Key Pipeline Programs at Virtual Investor Day Business Wire

Sep 9, 2020

08:30AM EDT Alexion Announces Upcoming Data Presentations at MSVirtual2020, the 8th Joint ACTRIMS - ECTRIMS Meeting Business Wire

Sep 3, 2020

06:30AM EDT Alexion to Present at Upcoming Virtual Investor Conferences Business Wire

Sep 1, 2020

09:23AM EDT Stifel Maintains Hold on Alexion Pharmaceuticals, Lowers Price Target to $117 Benzinga

Aug 6, 2020

08:03AM EDT Alexion Appoints Uzair Qadeer As First Chief Diversity Officer RTTNews

08:00AM EDT Alexion Announces Appointment of First Chief Diversity Officer Business Wire

Aug 4, 2020

11:41AM EDT Cramer Weighs In On Becton Dickinson, Vale And More Benzinga

Jul 31, 2020

10:04AM EDT Raymond James Maintains Outperform on Alexion Pharmaceuticals, Lowers Price Target to $151 Benzinga

06:38AM EDT SVB Leerink Maintains Outperform on Alexion Pharmaceuticals, Raises Price Target to $163 Benzinga

Jul 30, 2020

07:50AM EDT Recap: Alexion Pharmaceuticals Q2 Earnings Benzinga

07:11AM EDT Alexion Pharmaceuticals, Inc. (ALXN) said, for fiscal 2020, the company now expects non-GAAP earnings per share in a range of $10.65 to $10.95, revised from prior guidance range of $10.45 to $10.75. Total revenues are now projected in a range of $5.55 billion to $5.60 billion, revised from prior guidance range of $5.23 billion to $5.33 billion. RTTNews

06:39AM EDT Alexion Pharmaceuticals Raises FY20 Adj. EPS Guidance From $10.45-10.75 To $10.65-$10.95 vs $10.88 Est., Raises Sales Guidance From $5.23B-$5.33B To $5.55B-$5.6B vs $5.41B Est. Benzinga

06:36AM EDT Alexion Pharmaceuticals Q2 Adj. EPS $3.11 Beats $2.59 Estimate, Sales $1.44B Beat $1.28B Estimate Benzinga

06:34AM EDT Alexion Q2 Loss/Shr $4.84 Vs EPS $2.04 Last Year RTTNews

06:31AM EDT Alexion Reports Second Quarter 2020 Results Business Wire

04:06AM EDT Earnings Scheduled For July 30, 2020 Benzinga

Jul 16, 2020

06:30AM EDT Alexion to Report Second Quarter 2020 Results on Thursday, July 30, 2020 Business Wire